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Abstract
Current evidence suggests that statins may improve outcome in infectious diseases. This study aims to assess whether statins use is
associated with reduced risk of 30-day mortality in Clostridium difﬁcile infection (CDI). Using the computerized database of Clalit, the largest
healthcare provider in Israel, we identiﬁed a cohort of adult subjects (age ≥40 years) who tested positive on a C. difﬁcile toxin assay
performed between January 2011 and December 2012. Subjects were deﬁned as current statins users if they ﬁlled at least one prescription
during the 90 days before the laboratory assay date. Current users were classiﬁed into long-term users if at least one additional prescription
was ﬁlled during the previous 91–180 days; otherwise they were deﬁned as short-term users. A total 1888 patients with CDI were included.
Of them, 340 (18.0%) died during the ﬁrst 30 days after diagnosis. The 30-day mortality rate was lower among current statins users 89/669
(13.3%) compared with 251/1219 (20.6%) in non-users (p <0.001). A signiﬁcant reduced risk of 30-day mortality existed after adjustment for
potential confounders; adjusted OR = 0.57 (95% CI 0.42–0.79) and was unique to long-term users; 0.53 (0.38–0.73) but not short-term
users; 1.15 (0.56–2.34). The risk of 30-day mortality decreased with increasing number of ﬁlled statins prescriptions; adjusted OR = 0.77
(95% CI 0.67–0.89) for each additional prescription. Current aspirin use was also independently associated with reduced mortality; adjusted
OR = 0.64 (95% CI 0.43–0.88). In conclusion, current statins use, particularly long-term use, has a dose–response protective effect on
mortality in patients with CDI.
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Introduction
Clostridium difﬁcile is an anaerobic gram-positive, spore-form-
ing, toxin-producing bacillus that causes intestinal inﬂammation
and diarrhoea [1]. The clinical course of C. difﬁcile infections
(CDI) ranges from uncomplicated diarrhoea to pseudomem-
branous colitis, toxic megacolon and severe sepsis associated
with organ failure and increased risk of death [2]. In recent
years CDI was observed to be more frequent, severe,
refractory to standard treatment, and more likely to relapse
than previously described; this change in the pattern of the
disease is probably caused by new more virulent strains of
C. difﬁcile [3,4]. All-cause 30-day mortality in CDI varies from
9% to 38% with most studies showing a mortality rate of 15%
or greater [5]. When adjusted for age, sex and comorbidities
CDI patients had a 2.5-fold increased 30-day mortality rate
compared with controls without diarrhoea [6,7].
Increasing evidence suggests that besides their lipid-lower-
ing effect, statins have potent anti-inﬂammatory effects that
contribute to their beneﬁcial effects in cardiovascular disease
[8]. Statins use has been associated with reduced risk of
infection including reduced risk of CDI [9–11]. Several
observational studies have shown that statins use is associated
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with decreased mortality in patients with sepsis [12–15].
However, it has been suggested that a healthy user effect may
account for the observed beneﬁt [16].
Death from CDI ultimately follows severe complications of
sepsis. Because severe sepsis seems to be mediated by
inﬂammatory cytokines, agents like statins that have
anti-inﬂammatory and immunomodulatory properties might
have a beneﬁcial effect on mortality in patients with CDI. In
this study we aimed to assess whether current statins use is
associated with reduced risk of mortality in patients with CDI
controlling for the possibility of healthy user effect.
Materials and Methods
The database
The Clalit Health Services (CHS) is a not-for-proﬁt health-
care provider covering more than half of the Israeli
population (4 225 799 members) [17,18]. The centralized
electronic database of the CHS includes data from multiple
sources; primary-care physicians, specialty clinics in the
community, hospitalizations, laboratories and pharmacies. A
chronic disease registry is compiled from these data sources.
Diagnoses are captured in the registry by diagnosis-speciﬁc
algorithms, employing both code reading (e.g. ICD-9, ICPC)
and text reading. A record is kept of the sources and dates
are used to establish the diagnosis with the earliest
recorded date being considered the starting date of the
diagnosis.
Members of CHS may ﬁll prescriptions at any pharmacy
belonging to the CHS with low co-payment. All ﬁlled
prescriptions are captured in the CHS computerized database.
Because of the low co-payment it is unlikely that prescriptions
are purchased in private, non-CHS, pharmacies. Hence, we can
determine use of statins and other medications, as well as
other medical background data with great precision. More-
over, the low co-payment makes statins use unlikely to be
affected by affordability, which is a marker of mortality.
Study population
The CHS laboratory database was searched for all C. difﬁcile
toxin assays performed between 1 January 2011 and 31
December 2012. The ﬁrst positive assay during the study
period was selected (index date). We identiﬁed 1888 subjects,
age ≥40 years at index date, who tested positive for CDI
during this period.
Follow-up
The cohort of subjects with positive C. difﬁcile assay was
followed-up for all-cause mortality occurring during the
30 days starting on the index date. The date of death was
extracted from the vital status records of CHS, which are
updated monthly against the National Death Index. The cause
of death was unavailable.
Statins exposure deﬁnition
Exposure to statins treatment was analysed in three ways: (i)
Current statins users, (dichotomous variable, yes versus no)
if at least one prescription was ﬁlled during the 90 days
before the index date; (ii) and (iii) Current statins users were
further classiﬁed into two categories, short-term users and
long-term users; (ii) Short-term statins use was deﬁned as at
least one prescription ﬁlled during the 90 days before the
index date and no prescription ﬁlled between 91 and
180 days before the index date, (iii) Long-term users were
deﬁned as those who had at least one prescription ﬁlled
during each of the periods. To further assess the effect of
adherence to statins use (a proxy for dose–response effect)
on mortality, we calculated the number of statins prescrip-
tions ﬁlled during the 90 days before the index date (ordinal
variable) among current users. Generally the number of
prescriptions ﬁlled during this period ranged from none
(non-users) to four prescriptions, considering that a maxi-
mum of three statins prescriptions could be used during
90 days, this variable was grouped into four categories (0, 1,
2 and ≥3 prescriptions).
Covariates
The following covariates were considered as potential con-
founders: comorbid conditions present before the index date
including ischaemic heart disease, congestive heart failure,
stroke, diabetes, renal failure, hypertension, chronic obstruc-
tive pulmonary disease, obesity, liver cirrhosis, inﬂammatory
bowel disease and cancer in the previous year, were identiﬁed
from the CHS chronic disease registry. Hospitalizations (for
any cause) within 90 days before the index date were
identiﬁed from the CHS hospitalization database.
Treatment with antibiotics, chemotherapy, proton pump
inhibitors and aspirin were ascertained if any such prescription
was ﬁlled during the 90 days before the index date.
Clostridium difﬁcile assay
The diagnosis of C. difﬁcile at CHS laboratories is done using a
two-step algorithm: the ﬁrst step is an enzyme immunoassay
for C. difﬁcile toxins A and B and an enzyme immunoassay for
C. difﬁcile glutamate dehydrogenase (GDH). If the toxin assay is
positive then the test is considered positive. If the toxin assay
is negative and the GDH assay is positive, a second test
(second step) is performed consisting of PCR to detect toxin B
genes.
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Statistical methods
Comparisons of means between two groups were tested with
the Student’s t-test. The chi-squared test was used to compare
proportions between categorical variables.
We used logistic regression to assess the univariate and
multivariate association between statins use and 30-day
all-cause mortality. All covariates, included in the multivariate
model, were checked against one another for collinearity. We
assessed the association of 30-day all-cause mortality both
with statins use as one group (any statin) and with the speciﬁc
statin type (simvastatin, atorvastatin, pravastatin, rosuvastatin).
A p-value <0.05 for the two-tailed test was considered
statistically signiﬁcant. All statistical analyses were performed
using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
Correcting for a possible healthy user effect
As patients who use statins for primary or secondary
prevention are more likely to also seek other preventive
services and to engage in healthy behaviours leading to a
healthy user effect [19,20], measures were taken to correct
for such a possible effect.
One approach involves the evaluation of negative control
exposure [19,21]. In such a design the exposure would not be
expected to have a biological effect on study outcome, but may
be inﬂuenced by health status or health-seeking behaviour in
the same way as the study exposure (statins in our study). In an
unbiased analysis, there would be no association between the
negative control exposure and the study outcome. For this
purpose we used calcium-channel blockers as a possible
negative control exposure given the lack of supporting
biological mechanism or clinical evidence that could explain a
protective effect (if present) on CDI mortality. The presence of
healthy user effect would be suggested if a protective effect
were also found for calcium-channel blocker users. On other
hand, if no association is detected for calcium-channel block-
ers, then if a protective effect of statins is found then such an
effect may be unlikely to be attributable to healthy-user effect.
Results
Our study cohort includes 1888 subjects who were eligible to
be included in the study. The mean age of the patients was
75.7  12.6 years, and 1164 (61.7%) were females. The
baseline characteristics of the study population are presented
in Table 1.
Statins use and all-cause 30-day mortality
Overall 340 (18.0%) subjects with CDI died within 30 days of
CDI diagnosis. All subjects had complete 6-month follow up
when the data were retrieved from the database, during this
period 668 (35.4%) subjects died. It follows that about half of
deaths occurring during 6 months occurred during the ﬁrst
30 days.
Of the total 669 current statins users, 89 (13.3%) died
within 30 days, compared with 251/1219 (20.6%) among
non-users (p <0.001; Table 2). The decreased risk of 30-day
mortality persisted on multivariate analysis; adjusted
OR = 0.57 (95% CI 0.42–0.79; Table 2 and see Supporting
information, Table S1). The multivariate logistic regression
model showed that current aspirin use was also associated
with decreased risk of 30-day mortality; adjusted OR = 0.64
(95% CI 0.43–0.88). Similar risk estimates of aspirin effect
were reached on stratiﬁed analysis according to current
statins use; OR = 0.62 (95% CI 0.40–0.96) among non-statins
users, and 0.63 (95% CI 0.38–1.04) among statins users (see
Supporting information, Table S2). In addition, the effect of
statins use persisted on stratiﬁed analysis according to
aspirin treatment; OR = 0.55 (95% CI 0.32–0.95) among
aspirin users, and 0.57 (95% CI 0.38–0.86) among non-aspirin
users.
Compared with non-statin users, the crude odds for 30-day
mortality was 0.54 (95% CI 0.41–0.72) for long-term statins
users, and 1.22 (95% CI 0.65–2.32) for short-term statins users
TABLE 1. Baseline characteristics of the study subjects by






Yes (n = 669) No (n = 1219)
Age (years)
Mean  SD 75.7  12.6 76.6  10.3 75.2  13.7
Median (interquartile
range)
78 (68–85) 79 (70–84) 78 (66–86)
Gender
Females 1164 (61.7%) 402 (60.1%) 762 (62.5%)
Males 724 (38.3%) 267 (39.9%) 457 (37.5%)
Ethnicity
Jews 1804 (95.6%) 646 (96.6%) 1158 (95.0%)
Arabs 84 (4.4%) 23 (3.4%) 61 (5.0%)
Hospitalization in the
prior 90 days
1197 (63.4%) 444 (66.4%) 453 (61.8%)
Comorbidities
Ischaemic heart disease 670 (35.5%) 331 (49.5%) 339 (27.8%)
Previous stroke 502 (26.6%) 186 (27.8%) 316 (25.9%)
Congestive heart failure 390 (20.7%) 186 (27.8%) 204 (16.7%)
Chronic obstructive lung
disease
254 (13.5%) 113 (16.9%) 141 (11.6%)
Renal failure 555 (29.4%) 217 (32.4%) 338 (27.7%)
Diabetes mellitus 522 (27.6%) 251 (37.5%) 271 (22.2%)
Hypertension 1167 (61.8%) 502 (75.0%) 665 (54.6%)
Liver cirrhosis 21 (1.1%) 0 (0.0%) 21 (1.7%)
Obesity 457 (24.2%) 218 (32.6%) 239 (19.6%)
Inﬂammatory bowel
disease
59 (3.1%) 23 (3.4%) 36 (3.0%)
Previous cancer 113 (6.0%) 39 (5.8%) 74 (6.1%)
Medication use in the prior 90 days
Antibiotics 800 (42.4%) 362 (54.1%) 438 (35.9%)
Chemotherapy 65 (3.4%) 26 (3.9%) 39 (3.2%)
Aspirin 543 (28.8%) 357 (53.4%) 186 (15.3%)
Proton pump inhibitors 668 (34.9%) 336 (50.2%) 322 (26.4%)
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(Table 2). Similar risk estimates were reached on multivariate
analysis. Compared with non-statin users, the odds for 30-day
mortality was 0.53 (95% CI 0.38–0.73) for long-term statins
users, and 1.15 (95% CI 0.56–2.34) for short-term statins users
(Table 2 and Table S1).
All-cause 30-day mortality rate decreased with increasing
number of prescriptions ﬁlled during the previous 90 days
among current statins user (p <0.001; Table 2). The signiﬁcant
association with 30-day mortality and the number of prescrip-
tions persisted on multivariate analysis; adjusted OR = 0.77
(95% CI 0.67–0.89) for each additional prescription (Table 2
and Table S1). We performed sensitivity analysis to assess the
relationship between the number of prescriptions ﬁlled during
the previous 180 days and 30-day mortality, and similarly the
adjusted OR was 0.88 (95% CI 0.82–0.94) for each additional
prescription.
Statin type and 30-day mortality
Simvastatin was the most frequently used statin (437; 65.3%)
followed by atorvastatin (117; 17.5%), pravastatin (72; 10.8%)
and rosuvastatin (43; 6.4%). Except for the less frequently used
rosuvastatin, all other statins were independently associated
with reduced risk of 30-day mortality, the adjusted OR ranged
from 0.24 (pravastatin) to 0.64 (simvastatin; Table 3).
The negative control exposure and 30-day mortality
We employed the same exposure criteria to analyse exposure
to calcium-channel blockers, which were used as negative
control exposure. Calcium-channel blockers were not associ-
ated with 30-day mortality in any of the three different
exposure deﬁnition categories (Table 4 and see Supporting
information, Table S3).
Discussion
Our study shows that current statins use is associated with
reduced risk of 30-day mortality in patients with CDI. This
ﬁnding is consistent with other studies that showed protective
effect of statins against mortality in patients with sepsis
[12,13,15]. Although only a few patients were short-term
users, our ﬁndings suggest that long-term statins use but not
short-term use is associated with reduced risk of 30-day
mortality in patients with CDI. Long-term statins use was
found to better reduce 30-day mortality than short-term use
in patients with bacteraemia [13]. In addition, a dose–response
relationship of decreased 30-day mortality risk with increasing
the number of prescriptions ﬁlled by statins users was
demonstrated in our study. Further, the lack of association
between 30-day mortality and the negative exposure control
(calcium-channel blockers) makes the possibility of a healthy
user effect less likely. This fact is also supported by the ﬁnding
Statins use classiﬁcation category
Risk of 30-day mortality
Number of
deaths (%)* Crude OR (95% CI) Adjusteda OR (95% CI)
Current users (two categories)b
No (n = 1219) 251 (20.6) Reference Reference
Yes (n = 669) 89 (13.3) 0.59 (0.46–0.77) 0.57 (0.42–0.79)
Current users (three categories)c
No (n = 1219) 251 (20.6) Reference Reference
Short-term users (n = 54) 13 (24.1%) 1.22 (0.65–2.32) 1.15 (0.56–2.34)
Long-term users (n = 615) 76 (12.4%) 0.54 (0.41–0.72) 0.53 (0.38–0.73)
Prescriptions numberd
OR for increase in 1 prescription 0.77 (0.68–0.87) 0.77 (0.67–0.89)
None (n = 1219) 215 (20.6%)
1 prescription (n = 196) 33 (16.8%)
2 prescriptions (n = 217) 29 (13.4%)
≥3 prescriptions (n = 256) 27 (10.5%)
aAdjusted for demographic variables, comorbidities and medications use included in Table 1.
bCurrent statins use (Yes) was deﬁned if at least one prescription was ﬁlled during the 90 days before the index date.
cShort-term statins use was deﬁned if at least one prescription was ﬁlled during the 90 days before the index date and no
prescription were ﬁlled between 91 and 180 days before the index date, long-term users were deﬁned as those who had
at least one prescription ﬁlled during each period.
dThe number of statins prescription ﬁlled during the 90 days before the index date.
*p <0.001 for all group comparison.
TABLE 2. Crude and adjusted ORs
for the association between statins
use and 30-day mortality using three
different classiﬁcations for current
statins use, cohort of patients with
Clostridium difﬁcile infection
TABLE 3. Crude and adjusteda ORs for the association of









Any statin 669 (100) 0.59 (0.46–0.77) 0.57 (0.42–0.79)
Simvastatin 437 (65.3) 0.77 (0.53–0.95) 0.64 (0.45–0.91)
Atorvastatin 117 (17.5) 0.40 (0.21–0.76) 0.45 (0.22–0.92)
Pravastatin 72 (10.8) 0.23 (0.08–0.63) 0.24 (0.08–0.69)
Rosuvastatin 43 (6.4) 0.63 (0.26–1.50) 1.19 (0.44–3.19)
aAdjusted for demographic variables, comorbidities and medications use included
in Table 1.
b% of use out of all statins users.
cOR for current users compared with non-current users.
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that aspirin use which shares common anti-inﬂammatory
properties with statins was also associated with reduced risk
of 30-day mortality in patients with CDI.
Different aspects of the relationship between statins and
CDI were previously studied. Previous statins use was found
to be associated with reduced risk of CDI [10,11]. Previous
statins use in patients with CDI was also found to be
associated with successful response to treatment and reduced
risk of CDI recurrence [22]. However, the same study did not
ﬁnd a statistically signiﬁcant association between statins use
and 30-day mortality among patients with CDI, but authors
suggested that their study was underpowered to detect
survival beneﬁt [22].
Plausible explanations for our ﬁndings are the anti-inﬂam-
matory and immunomodulatory properties of statins [8],
through which they may reduce the severity of CDI and
consequently reduce mortality from CDI. This theory is
further supported by our ﬁnding of reduced risk of mortality
associated with aspirin, which shares anti-inﬂammatory prop-
erties with statins. In addition, both C. difﬁcile toxin B and
statins potentiate cytokine-induced nitric oxide synthase II
expression through inhibition of small G proteins of the Rho
family. A sudden high nitric oxide synthase II induction can lead
to septic shock and death [23]. Hence, people who have been
taking statins over a long period (but not short-term users)
may be protected because their bodies have a constant basal
state of inhibition of these small G proteins, so that C. difﬁcile
toxin B exposure is less harmful. However, the persistence of
the protective effect of aspirin among non-statins users makes
this explanation less likely.
The protective effect on acquiring CDI was found to be
similar between the various statin types with an overall
estimate of OR = 0.78 (95% CI 0.75–0.81) [11]. In line with
these ﬁndings the beneﬁcial effect on mortality in our study
seems to be common to all statins (except rosuvastatin) with
some variability in the individual statins-speciﬁc estimates
(ranging from 0.24 to 0.64). Larger studies are needed to best
assess the association between the individuals statins and
30-day mortality in patients with CDI.
Our study has several limitations; the main possible
limitation of our study design is the case deﬁnition of CDI in
that it was based only on the presence of positive C. difﬁcile
toxin assay as we had no data to ascertain whether the clinical
presentation was also consistent with CDI. However, the
instructions for all CHS microbiological laboratories are to
perform C. difﬁcile toxin assay only on ﬂuid stool samples.
Although this may result in misclassiﬁcation it is likely to be
non-differential and is expected to bias the estimates toward
the null. In this study we used 30-day all-cause mortality
because we did not have data on speciﬁc causes of death, and
therefore we could not state whether the reduced risk of
mortality associated with statins use is a direct result of
reduced CDI mortality. However, 30-day all-cause mortality is
acceptable in studies that assessed mortality in patients with
CDI [5,24]. Further, a previous study has found that
CDI-related deaths occurred mainly within 30 days after
diagnosis [6]. In addition, this study shows that more than
half of deaths detected in the ﬁrst 6 months have occurred
during the ﬁrst 30 days. which strongly suggests that most
deaths occurring during the ﬁrst 30 days may be attributable
to CDI. Although we have adjusted for a large number of risk
factors of mortality, our study may still suffer from residual
confounding, therefore a cause and effect relationship cannot
be proven by our study.
In conclusion, current and long-term statins use provides
protection with a dose–response relationship against 30-day
TABLE 4. Crude and adjusted ORs
for the association of negative con-
trol exposure (calcium-channel
blockers) with 30-day mortality in




Risk of 30-day mortality
Number of
deaths (%) Crude OR (95% CI) Adjusteda OR (95% CI)
Current users (two categories)b
No (n = 1493) 271 (18.2) Reference Reference
Yes (n = 395) 69 (17.5) 0.95 (0.71–1.28) 0.84 (0.60–1.18)
Current users (three categories)c
No (n = 1493) 271 (18.2) Reference Reference
Short-term users (n = 52) 11 (21.2) 1.21 (0.61–2.38) 1.30 (0.62–2.75)
Long-term users (n = 343) 58 (16.9) 0.92 (0.67–1.25) 0.79 (0.55–1.13)
Prescription numberd
OR for increase in 1 prescription 0.93 (0.81–1.07) 0.90 (0.77–1.05)
None (n = 1493) 271 (18.2)
1 prescription (n = 129) 27 (20.9)
2 prescriptions (n = 123) 24 (19.6)
≥3 prescriptions (n = 143) 18 (12.6)
aAdjusted for demographic variables, comorbidities and medications use included in Table 1.
bCurrent calcium-channel blocker use (yes) was deﬁned if at least one prescription was ﬁlled during the 90 days before
the index date.
cShort-term calcium-channel blocker use was deﬁned if at least one prescription was ﬁlled during the 90 days before the
index date and no prescription was ﬁlled between 91 and 180 days before the index date, long-term users were deﬁned
as those who had at least one prescription ﬁlled during each period.
dThe number of calcium-channel blocker prescriptions ﬁlled during the 90 days before the index date.
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mortality in patients with CDI. The beneﬁcial effect of statins
appears to be common to most statins with an additional
suggestive beneﬁcial effect of aspirin.
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Table S1. Multivariatea analysis of the association between
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